This page shows the latest Rinvoq news and features for those working in and with pharma, biotech and healthcare.
The latter group includes Pfizer’s Xeljanz, (tofacitinib), Eli Lilly’s Olumiant (baricitinib) and AbbVie’s Rinvoq (upadacitinib), which have been approved for rheumatoid arthritis but are also in testing for
news. Quick take-up of new immunology drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) have encouraged AbbVie to predict the pair will together make around $1.7bn in sales this year, well ... Meanwhile, selective JAK inhibitor Rinvoq added another
This includes psoriasis treatment Skyrizi, Rinvoq, medical Botox, and cancer treatments Imbruvica and Veclexta.
The pharma company has been pushing Rinvoq (upadacitinib) into the RA market, while its Boehringer Ingelheim-partnered drug Skyrizi (risankizumab) has been making headway in psoriasis. ... Across these phase 3 studies, Rinvoq met all its primary and
This includes a new class of JAK inhibitors, such as AbbVie’s Rinvoq (upadacitinib), Pfizer’s Xeljanz (tofacitinib) and Eli Lilly’s Olumiant (baricitinib). ... ICER’s conclusion that Rinvoq, in particular, only had a ‘marginal’ benefit over
ICER’s original report concluded that the incremental cost-effectiveness of Rinvoq versus AbbVie’s ageing blockbuster Humira exceeded its $150, 000 threshold. ... According to ICER, this evidence demonstrates that Rinvoq provides a small to
More from news
Approximately 3 fully matching, plus 5 partially matching documents found.
JAK inhibitors such as Xeljanz and Rinvoq.
AbbVie needs its new products to deliver quickly, and that includes recently approved JAK inhibitor Rinvoq (upadacitinib) for arthritis and psoriasis therapy Skyrizi (risankizumab) – both tipped as possible future blockbusters despite
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...